No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + ixazomib Sensitive: A1 - Approval lenalidomide + ixazomib Sensitive : A1	lenalidomide + ixazomib Sensitive: A1 - Approval lenalidomide + ixazomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ixazomib Sensitive: A2 - Guideline ixazomib Sensitive : A2	ixazomib Sensitive: A2 - Guideline ixazomib Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: A2 - Guideline rituximab + ixazomib Sensitive : A2	rituximab + ixazomib Sensitive: A2 - Guideline rituximab + ixazomib Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ixazomib + pomalidomide Sensitive: A2 - Guideline ixazomib + pomalidomide Sensitive : A2	ixazomib + pomalidomide Sensitive: A2 - Guideline ixazomib + pomalidomide Sensitive : A2
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2
MYD88 L265P	Waldenstrom Macroglobulinemia	MYD88 L265P	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2
Chr t(14;16)	Multiple Myeloma	Chr t(14;16)	Multiple Myeloma	ixazomib Sensitive: C2 – Inclusion Criteria ixazomib Sensitive : C2	ixazomib Sensitive: C2 – Inclusion Criteria ixazomib Sensitive : C2
CXCR4 G336X	Waldenstrom Macroglobulinemia	CXCR4 G336X	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3
CXCR4 S338X	Waldenstrom Macroglobulinemia	CXCR4 S338X	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3
CXCR4 H350fs*	Waldenstrom Macroglobulinemia	CXCR4 H350fs*	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3
CXCR4 S338X + TP53 R196X	Waldenstrom Macroglobulinemia	CXCR4 S338X + TP53 R196X	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3
CXCR4 K327fs*	Waldenstrom Macroglobulinemia	CXCR4 K327fs*	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3
CXCR4 R338X	Waldenstrom Macroglobulinemia	CXCR4 R338X	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3
CXCR4 T318fs*	Waldenstrom Macroglobulinemia	CXCR4 T318fs*	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3
CXCR4 L326fs*	Waldenstrom Macroglobulinemia	CXCR4 L326fs*	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3
CXCR4 S347fs*	Waldenstrom Macroglobulinemia	CXCR4 S347fs*	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3
Chr amplification(1q)	Multiple Myeloma	Chr amplification(1q)	Multiple Myeloma	lenalidomide + ixazomib Sensitive: C3 – Early Trials lenalidomide + ixazomib Sensitive : C3	lenalidomide + ixazomib Sensitive: C3 – Early Trials lenalidomide + ixazomib Sensitive : C3
Chr del(17p)	Multiple Myeloma	Chr del(17p)	Multiple Myeloma	lenalidomide + ixazomib Sensitive: C3 – Early Trials lenalidomide + ixazomib Sensitive : C3	lenalidomide + ixazomib Sensitive: C3 – Early Trials lenalidomide + ixazomib Sensitive : C3
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	lenalidomide + ixazomib Sensitive: C3 – Early Trials lenalidomide + ixazomib Sensitive : C3	lenalidomide + ixazomib Sensitive: C3 – Early Trials lenalidomide + ixazomib Sensitive : C3
Chr del(17)(p13)	Multiple Myeloma	Chr del(17)(p13)	Multiple Myeloma	ixazomib Sensitive: C3 – Early Trials ixazomib Sensitive : C3	ixazomib Sensitive: C3 – Early Trials ixazomib Sensitive : C3
NFKB2 negative	Multiple Myeloma	NFKB2 negative	Multiple Myeloma	ixazomib Sensitive: C3 – Early Trials ixazomib Sensitive : C3	ixazomib Sensitive: C3 – Early Trials ixazomib Sensitive : C3
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	ixazomib Sensitive: C3 – Early Trials ixazomib Sensitive : C3	ixazomib Sensitive: C3 – Early Trials ixazomib Sensitive : C3
Chr t(14;16)	Multiple Myeloma	Chr t(14;16)	Multiple Myeloma	lenalidomide + ixazomib Sensitive: C3 – Early Trials lenalidomide + ixazomib Sensitive : C3	lenalidomide + ixazomib Sensitive: C3 – Early Trials lenalidomide + ixazomib Sensitive : C3
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	ixazomib Sensitive: C4 – Case Studies ixazomib Sensitive : C4	ixazomib Sensitive: C4 – Case Studies ixazomib Sensitive : C4
FLT3 mutation + DNMT3A mutation	Acute Myelogenous Leukemia	FLT3 mutation + DNMT3A mutation	Acute Myelogenous Leukemia	ixazomib Resistant: D – Preclinical ixazomib Resistant : D	ixazomib Resistant: D – Preclinical ixazomib Resistant : D
FLT3 mutation + MLL mutation	Acute Myelogenous Leukemia	FLT3 mutation + MLL mutation	Acute Myelogenous Leukemia	ixazomib Resistant: D – Preclinical ixazomib Resistant : D	ixazomib Resistant: D – Preclinical ixazomib Resistant : D
FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	ixazomib Resistant: D – Preclinical ixazomib Resistant : D	ixazomib Resistant: D – Preclinical ixazomib Resistant : D
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	ixazomib Sensitive: D – Preclinical ixazomib Sensitive : D	ixazomib Sensitive: D – Preclinical ixazomib Sensitive : D
ALK rearrangement + TP53 mutation	Non Small Cell Lung Cancer	ALK rearrangement + TP53 mutation	Non Small Cell Lung Cancer	alectinib + ixazomib Sensitive: D – Preclinical alectinib + ixazomib Sensitive : D	alectinib + ixazomib Sensitive: D – Preclinical alectinib + ixazomib Sensitive : D
PDZK1IP1 overexpression	Pancreatic Cancer	PDZK1IP1 overexpression	Pancreatic Cancer	ixazomib Resistant: D – Preclinical ixazomib Resistant : D	ixazomib Resistant: D – Preclinical ixazomib Resistant : D
PDZK1IP1 expression	Pancreatic Cancer	PDZK1IP1 expression	Pancreatic Cancer	ixazomib Resistant: D – Preclinical ixazomib Resistant : D	ixazomib Resistant: D – Preclinical ixazomib Resistant : D

Ninlaro (ixazomib)

Associations
(31)

Associations
(31)

Ninlaro (ixazomib)

Associations(31)

Associations(31)

Associations
(31)

Associations
(31)